Salud financiera de hoja de balance de Ascletis Pharma

Salud financiera controles de criterios 6/6

Ascletis Pharma tiene un patrimonio de los accionistas total de CN¥2.2B y una deuda total de CN¥0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son CN¥2.3B y CN¥95.8M respectivamente.

Información clave

Ratio deuda-patrimonio

CN¥0

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	CN¥2.09b
Patrimonio	CN¥2.18b
Total pasivo	CN¥95.79m
Activos totales	CN¥2.28b

Actualizaciones recientes sobre salud financiera

Here's Why We're Not Too Worried About Ascletis Pharma's (HKG:1672) Cash Burn Situation

May 19

We're Hopeful That Ascletis Pharma (HKG:1672) Will Use Its Cash Wisely

Feb 08

Recent updates

Is Ascletis Pharma (HKG:1672) In A Good Position To Deliver On Growth Plans?

Oct 07

We're Not Very Worried About Ascletis Pharma's (HKG:1672) Cash Burn Rate

Dec 19

We're Hopeful That Ascletis Pharma (HKG:1672) Will Use Its Cash Wisely

Aug 23

What You Need To Know About The Ascletis Pharma Inc. (HKG:1672) Analyst Downgrade Today

Nov 03

Companies Like Ascletis Pharma (HKG:1672) Can Afford To Invest In Growth

Oct 13

Need To Know: Analysts Just Made A Substantial Cut To Their Ascletis Pharma Inc. (HKG:1672) Estimates

Aug 24

Here's Why We're Not Too Worried About Ascletis Pharma's (HKG:1672) Cash Burn Situation

May 19

Ascletis Pharma Inc.'s (HKG:1672) Sole Analyst Just Made A Dazzling Upgrade To Their Forecasts

Mar 27

We're Hopeful That Ascletis Pharma (HKG:1672) Will Use Its Cash Wisely

Feb 08

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo (CN¥2.1B) de 1672 superan a sus pasivos a corto plazo (CN¥86.8M).

Pasivo a largo plazo: Los activos a corto plazo de 1672 (CN¥2.1B) superan a sus pasivos a largo plazo (CN¥9.0M).

Historial y análisis de deuda-patrimonio

Nivel de deuda: 1672 está libre de deudas.

Reducción de la deuda: 1672 no ha tenido ninguna deuda en los últimos 5 años.

Hoja de balance

Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: 1672 tiene suficiente cash runway para más de 3 años basándose en su flujo de caja libre actual.

Pronóstico de cash runway: 1672 dispone de suficiente cash runway para más de 3 años si el flujo de caja libre sigue reduciéndose a tasas históricas de 9.4% cada año

Salud financiera de hoja de balance de Ascletis Pharma

Salud financiera controles de criterios 6/6

Información clave

Actualizaciones recientes sobre salud financiera

Is Ascletis Pharma (HKG:1672) In A Good Position To Deliver On Growth Plans?

We're Not Very Worried About Ascletis Pharma's (HKG:1672) Cash Burn Rate

We're Hopeful That Ascletis Pharma (HKG:1672) Will Use Its Cash Wisely

Companies Like Ascletis Pharma (HKG:1672) Can Afford To Invest In Growth

Here's Why We're Not Too Worried About Ascletis Pharma's (HKG:1672) Cash Burn Situation

We're Hopeful That Ascletis Pharma (HKG:1672) Will Use Its Cash Wisely

Recent updates

Ascletis Completes Enrollment of Phase III Trial of ASC40 (Denifanstat) Once-Daily Oral Tablet for Treatment of Acne

New major risk - Revenue and earnings growth

Is Ascletis Pharma (HKG:1672) In A Good Position To Deliver On Growth Plans?

Update on Legal Proceedings Involving Ascletis Pharma Inc.'s ASC41 and ASC43F

Ascletis Pharma Inc. Enters the Obesity Drug Space with Announcement of Two Ongoing U.S. Phase I Clinical Trials Utilizing Its Small Molecule GLP-1R Agonist ASC30 for Both Once-Monthly Subcutaneous Injection and Once-Daily Oral Tablet for the Treatment of Obesity

New minor risk - Revenue size

New minor risk - Share price stability

Ascletis Pharma Inc. to Report Q2, 2024 Results on Aug 30, 2024

Ascletis Pharma Inc. Announces Presentation Designing Positive Interim 12-Week Results from Phase II Clinical Trial of ASC41 in Patients with Biopsy- Confirmed Mash At EASL Congress 2024

Ascletis Pharma Inc., Annual General Meeting, May 23, 2024

Ascletis Pharma Inc. Announces Strategic Decisions on FXR Agonist ASC42

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Ascletis Pharma Inc. Announces Poster Presentation of Phase II Study Final Results of FASN Inhibitor ASC40 for Treatment of Acne at 2024 AAD Annual Meeting

Ascletis Pharma Inc. to Report Fiscal Year 2023 Results on Mar 25, 2024

Ascletis Pharma Inc. Announces Dosing of the First Patient in Phase III Clinical Trial of Asc40 (Denifanstat) for Treatment of Acne

New major risk - Revenue and earnings growth

Ascletis Pharma Inc. Announces Positive Interim Results from 52-Week Phase Ii Clinical Trial of Once-Daily Asc41 Tablet in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis

We're Not Very Worried About Ascletis Pharma's (HKG:1672) Cash Burn Rate

Ascletis Pharma Inc. Announces Initiation of Phase III Clinical Trial of ASC40 (Denifanstat) for Treatment of Acne

First half 2023 earnings: EPS exceeds analyst expectations

Ascletis Pharma Inc. Announces Positive Interim Data from the Phase IIb Expansion Cohort of ASC22 (Envafolimab) for Chronic Hepatitis B Functional Cure

Ascletis Pharma Inc. Announces Completion of Enrollment of 120 Patients in the Phase Ii Clinical Trial of FASN Inhibitor ASC40 Combined with Bevacizumab for Treatment of Recurrent Glioblastoma

Consensus revenue estimates decrease by 19%, EPS upgraded

We're Hopeful That Ascletis Pharma (HKG:1672) Will Use Its Cash Wisely

First half 2023 earnings released: CN¥0.015 loss per share (vs CN¥0.081 loss in 1H 2022)

New major risk - Revenue and earnings growth

Ascletis Pharma Inc. to Report Q2, 2023 Results on Aug 21, 2023

Ascletis Pharma Inc. Announces Completion of Patient Enrollment for Phase Ii Clinical Trial of Asc42, an Fxr Agonist, for Primary Biliary Cholangitis

New minor risk - Profitability

Consensus revenue estimates decrease by 22%, EPS upgraded

Ascletis Pharma Inc., Annual General Meeting, Jun 29, 2023

Ascletis Pharma Inc. Announces China NMPA Approval of Conducting a Phase IIa Clinical Trial for ASC10 to Treat Respiratory Syncytial Virus Infection

Full year 2022 earnings: EPS and revenues miss analyst expectations

Forecast breakeven date moved forward to 2023

Consensus revenue estimates decrease by 12%

Ascletis Pharma Inc. Announces Oral Presentation at APASL Annual Meeting 2023 Demonstrates ASC22, a Subcutaneous PD-L1 Antibody, Can Achieve Functional Cure of Chronic Hepatitis B

Consensus revenue estimates increase by 27%

Forecast breakeven date moved forward to 2023

Ascletis Pharma Announces U.S. FDA Approval of Conducting Phase IIA Clinical Trial for ASC10 to Treat Respiratory Syncytial Virus Infection

Ascletis Announces IND Approval of Oral Viral Polymerase Inhibitor ASC10 for Monkeypox Indication by China Nmpa

Ascletis Pharma Inc. Doses 4 Healthy Subjects of the First Cohort in Multiple-Dose Escalation Phase I Clinical Trial of Oral 3CLpro Inhibitor ASC11 for COVID-19

Viking Therapeutics, Inc. Files Complaints Against Ascletis Pharma Inc

Ascletis Announces Positive Phase I Clinical Results of Oral Rdrp Inhibitor Asc10 for Covid-19

Ascletis Pharma Inc. Announces IND Approval of Oral 3CLpro Inhibitor ASC11 for COVID-19 by China NMPA

Ascletis Announces Completion of 180 Patient Enrollment for Phase II Clinical Trial of FASN Inhibitor Asc40 for Acne

Ascletis Pharma Inc. Announces IND Filing of Oral 3CLpro Inhibitor ASC11 for COVID-19 Accepted by China NMPA

Ascletis Announces IND Approval of Oral 3CLpro Inhibitor ASC11 for Covid-19 by U.S. FDA

Ascletis Pharma Inc. Announces IND Approval of Oral PD-L1 Small Molecule Inhibitor ASC61 for Treatment of Advanced Solid Tumors by China NMPA

Ascletis Pharma Inc. Announces IND Approval of Viral Polymerase Inhibitor ASC10 for Monkeypox Indication by U.S. FDA

Insufficient new directors

Ascletis Pharma Inc. Announces Poster Presentation of Phase I, Single-Dose Study of ASC43F for NASH at AASLD Annual Meeting 2022

What You Need To Know About The Ascletis Pharma Inc. (HKG:1672) Analyst Downgrade Today

Ascletis Announces U.S. IND Filing of Oral 3CLpro Inhibitor ASC11 for COVID-19

Consensus revenue estimates fall by 19%

Ascletis Pharma Inc. Announces U.S. IND Filing of Oral Antiviral ASC10 for Monkeypox Indication

Companies Like Ascletis Pharma (HKG:1672) Can Afford To Invest In Growth

Ascletis Announces Dosing of 24 Healthy Subjects of the First 3 Cohorts in Multiple-Dose Escalation Phase I Clinical Trial of Oral RdRp Inhibitor ASC10 for COVID-19

Ascletis Pharma Inc. Announces Dosing of the First Patient in Phase Ii Clinical Trial of Thrß Agonist Asc41 for 52-Week Treatment of Liver Biopsy-Proven Nash

Ascletis Announces Dosing of the First Patient in the Phase IIb Expansion Cohort of ASC22 (Envafolimab) for Chronic Hepatitis B Functional Cure

Ascletis Pharma Inc. Announces Clinical Study of PD-L1 antibody ASC22

Consensus revenue estimates fall by 13%

Need To Know: Analysts Just Made A Substantial Cut To Their Ascletis Pharma Inc. (HKG:1672) Estimates

First half 2022 earnings released: CN¥0.081 loss per share (vs CN¥0.10 loss in 1H 2021)

Ascletis Pharma Inc. Announces Change of Company Secretary

Ascletis Announces IND Approval of Oral RdRp Inhibitor ASC10 for COVID-19 by China NMPA

Vascletis Pharma Inc. Announces First Subject Dosed in the U.S. Drug-Drug Interaction Study of FXR Agonist ASC42 for Treatment of Primary Biliary Cholangitis

Ascletis Announces First Patient Dosed in the U.S. Phase I Clinical Trial of Oral PD-L1 Small Molecule Inhibitor Prodrug ASC61 for Treatment of Advanced Solid Tumors

Ascletis Announces IND Filing of Oral RdRp Inhibitor ASC10 for COVID-19 Accepted by China NMPA

Ascletis Announces FDA Clearance of Oral RdRp Inhibitor ASC10 to Conduct a Randomized, Placebo Controlled Phase Ib Study in Mild-to-Moderate COVID-19 Patients